- Trials with a EudraCT protocol (21)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
21 result(s) found for: Tigecycline.
Displaying page 1 of 2.
EudraCT Number: 2011-000064-10 | Sponsor Protocol Number: Fistula-SD-MD | Start Date*: 2011-03-17 |
Sponsor Name:Med. Univ. Wien, Klinik für klinische Pharmakologie | ||
Full Title: Target site pharmacokinetics of linezolid or tigecycline in patients with severe skin and skin structure infections (SSSI) associated with chronic fistulas. | ||
Medical condition: The findings of the present study will enable assessing whether currently employed therapy regimens with linezolid or tigecycline provide effective antimicrobial concentrations at the target site o... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2012-005617-39 | Sponsor Protocol Number: WS2030571 | Start Date*: 2014-01-14 |
Sponsor Name:University Hospital Tuebingen | ||
Full Title: Pharmacokinetics of Tigecycline in Patients Receiving Continuous Renal Replacement Therapy | ||
Medical condition: Surgical ICU patients with severe infection and renal replacement therapy | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-002257-76 | Sponsor Protocol Number: 3074K5-319-WW | Start Date*: 2006-12-20 | |||||||||||
Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc. | |||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Comparison Study of the Safety and Efficacy of a Once-Daily Dose of Tigecycline versus Ertapenem for the Treatment of Foot Infections in Subjects with Diabetes | |||||||||||||
Medical condition: Subjects with diabetes with a qualifying foot infection. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) BE (Completed) SE (Prematurely Ended) LT (Completed) SK (Completed) FI (Completed) GB (Completed) LV (Completed) PT (Completed) EE (Completed) FR (Completed) AT (Completed) GR (Completed) DE (Completed) IT (Prematurely Ended) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-005166-31 | Sponsor Protocol Number: 3074K4-3340-WW | Start Date*: 2009-09-15 | |||||||||||
Sponsor Name:Wyeth Pharmaceuticals Inc., acting through its division Wyeth Research, a Pfizer Company | |||||||||||||
Full Title: A Phase 3, Multicenter, Randomized, and Double-blind Study to Evaluate the Safety of Tigecycline versus a Ceftriaxone Regimen in the Treatment of Complicated Intra-abdominal Infections and Communit... | |||||||||||||
Medical condition: Complicated Intra-Abdominal Infection | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) HU (Completed) SI (Completed) GB (Completed) Outside EU/EEA | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-000412-33 | Sponsor Protocol Number: 3074K6-2000-WW | Start Date*: 2008-09-17 | |||||||||||
Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development | |||||||||||||
Full Title: A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, COMPARATIVE STUDY OF THE SAFETY AND EFFICACY OF 2 DOSES OF TIGECYCLINE VERSUS IMIPENEM/CILASTATIN FOR THE TREATMENT OF SUBJECTS WITH HOSPITAL-ACQUI... | |||||||||||||
Medical condition: Hospital-Acquired Pneumonia (HAP) including Ventilator-Associated Pneumonia (VAP) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Prematurely Ended) LV (Completed) FR (Completed) EE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-000448-99 | Sponsor Protocol Number: 3074A1-315-WW | Start Date*: 2005-12-12 |
Sponsor Name:Wyeth Pharmaceuticals, Inc., Global Medical Affairs | ||
Full Title: A Multicenter, Open-Label, Randomized Comparative Study of Tigecycline vs Ceftriaxone Sodium Plus Metronidazole for the Treatment of Hospitalized Subjects With Complicated Intra-abdominal Infection. | ||
Medical condition: Complicated Intra-Abdominal Infection | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) GB (Completed) ES (Completed) FI (Completed) DK (Completed) GR (Completed) PT (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-004250-28 | Sponsor Protocol Number: 3074A1-900 | Start Date*: 2006-09-22 |
Sponsor Name:Wyeth Pharmaceuticals, Inc. | ||
Full Title: A MULTICENTER, RANDOMIZED, OPEN-LABEL COMPARISON OF THE SAFETY AND EFFICACY OF TIGECYCLINE WITH THAT OF AMPICILLIN-SULBACTAM OR AMOXICILLIN-CLAVULANATE TO TREAT COMPLICATED SKIN AND SKIN STRUCTURE ... | ||
Medical condition: COMPLICATED SKIN AND SKIN STRUCTURE INFECTION | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) DE (Completed) FR (Completed) IT (Completed) PT (Completed) GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-000391-42 | Sponsor Protocol Number: MD-01 | Start Date*: 2013-01-22 |
Sponsor Name:Martin-Luther-Universität Halle-Wittenberg | ||
Full Title: Investigation on the peritoneal tissue concentrations of antibiotics in surgical patients with peritonitis using microdialysis. Example: linezolide, tigecycline | ||
Medical condition: Peritonitis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-006210-14 | Sponsor Protocol Number: GIMEMA01 | Start Date*: 2007-07-12 | |||||||||||
Sponsor Name:UNIVERSITA' DEGLI STUDI DI PERUGIA | |||||||||||||
Full Title: PIPERACILLIN/TAZOBACTAM PLUS TIGECYCLINE VS. PIPERACILLIN/TAZOBACTAM ALONE AS EMPIRICAL THERAPY FOR FEBRILE NEUTROPENIC CANCER PATIENTS : A PROSPECTIVE, RANDOMISED, MULTI-CENTRE, STUDY. | |||||||||||||
Medical condition: Neutropenic, febrile cancer patients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-001936-11 | Sponsor Protocol Number: 3074K4-3339-WW | Start Date*: 2009-03-20 | |||||||||||||||||||||||||||||||
Sponsor Name:Wyeth Pharmaceuticals Inc. | |||||||||||||||||||||||||||||||||
Full Title: A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Tigecycline Versus Clindamycin for the Treatment of Complicated Skin and Skin Structure Infections, Inc... | |||||||||||||||||||||||||||||||||
Medical condition: Complicated skin and skin structure infection (cSSSI) with or without methicillin-resistant Staphylococcus aureus (MRSA) | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: HU (Completed) BE (Completed) GB (Completed) Outside EU/EEA | |||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-002120-14 | Sponsor Protocol Number: 3074K4-2207-WW | Start Date*: 2008-10-29 | |||||||||||||||||||||
Sponsor Name:Wyeth Research Division of Wyeth Pharmaceutical Inc. | |||||||||||||||||||||||
Full Title: A Multicenter, Open-Label, Ascending Multiple-Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Tigecycline in Patients 8 to 11 Years of Age With Selected Serious Infections | |||||||||||||||||||||||
Medical condition: Complicated intra-abdominal infections (cIAI), complicated skin and skin structure infections (cSSSI), community-acquired pneumonia (CAP). | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: BE (Completed) GB (Completed) Outside EU/EEA | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2018-001082-17 | Sponsor Protocol Number: DELA-01 | Start Date*: 2019-08-19 | |||||||||||
Sponsor Name:MENARINI RICERCHE S.p.A. | |||||||||||||
Full Title: A randomized, observer-blinded, active-controlled, Phase IIIb study to compare IV / Oral delafloxacin fixed-dose monotherapy with best available treatments in a microbiologically enriched populatio... | |||||||||||||
Medical condition: Acute Bacterial Skin and Skin Structure Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Prematurely Ended) GB (Prematurely Ended) HU (Prematurely Ended) LV (Prematurely Ended) SI (Prematurely Ended) ES (Prematurely Ended) AT (Prematurely Ended) PL (Prematurely Ended) EE (Prematurely Ended) BG (Prematurely Ended) HR (Completed) IT (Prematurely Ended) RO (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000726-21 | Sponsor Protocol Number: D4280C00006 | Start Date*: 2012-09-11 | ||||||||||||||||
Sponsor Name:AstraZeneca AB | ||||||||||||||||||
Full Title: An Open-Label, Randomized, Multicenter, Phase III Study of Ceftazidime Avibactam (CAZ-AVI, formerly CAZ104) and Best Available Therapy for the Treatment of Infections Due to Ceftazidime Resistant G... | ||||||||||||||||||
Medical condition: cUTI, Complicated Urinary Tract Infection, cIAI, Complicated intra-abdominal infection | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: BE (Completed) DE (Completed) CZ (Completed) ES (Completed) GR (Completed) BG (Completed) HU (Completed) IT (Completed) GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2010-023814-29 | Sponsor Protocol Number: CAS110775 | Start Date*: 2011-06-17 | |||||||||||
Sponsor Name:Instituto Científico y Tecnológico de Navarra | |||||||||||||
Full Title: Concentración y actividad antibiótica en soluciones de sellado | |||||||||||||
Medical condition: Pacientes con catéter venoso central con reservorio subcutáneo | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000050-10 | Sponsor Protocol Number: FORMaT001 | Start Date*: 2023-01-02 | |||||||||||
Sponsor Name:University of Queensland | |||||||||||||
Full Title: Finding the Optimal Regimen for Mycobacterium abscessus Treatment | |||||||||||||
Medical condition: Mycobacterium abscessus pulmonary disease | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-004383-22 | Sponsor Protocol Number: Mikrodialyse | Start Date*: 2013-05-13 | ||||||||||||||||
Sponsor Name:University of Leipzig | ||||||||||||||||||
Full Title: Perioperative complications in obese and non-obese patients: Prevention and treatment of wound infections and post-operative pain. Prospective, open, monocentric study to investigate perioperative... | ||||||||||||||||||
Medical condition: Prophylactic antibiotics, wound infections and pain associated with elective surgery in obese patients | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2018-000492-32 | Sponsor Protocol Number: AMIII | Start Date*: 2019-01-14 |
Sponsor Name:Charité-Universitätsmedizin Berlin | ||
Full Title: Effects of antibiotics on micobiota, pulmonary immune response and incidence of ventilator-associated infections | ||
Medical condition: mechanically ventilated patients | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2021-001396-16 | Sponsor Protocol Number: OP0595-6 | Start Date*: 2023-03-29 | |||||||||||||||||||||||||||||||
Sponsor Name:Meiji Seika Pharma Co., Ltd. | |||||||||||||||||||||||||||||||||
Full Title: A Phase 3, Multi-Center, Randomized, Single-Blind Study to Assess the Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy in Adults With Complicated Ur... | |||||||||||||||||||||||||||||||||
Medical condition: Complicated urinary tract infection (cUTI), acute uncomplicated pyelonephritis (AP), hospital acquired bacterial pneumonia (HABP), ventilator-associated bacterial pneumonia (VABP), and complicated ... | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: FR (Trial now transitioned) SK (Trial now transitioned) GR (Trial now transitioned) LV (Trial now transitioned) ES (Ongoing) | |||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-000546-30 | Sponsor Protocol Number: Rempex-506 | Start Date*: 2015-04-21 | |||||||||||||||||||||||||||||||
Sponsor Name:Rempex Pharmaceuticals, Inc. | |||||||||||||||||||||||||||||||||
Full Title: A PHASE 3, MULTI-CENTER, RANDOMIZED, OPEN-LABEL STUDY OF CARBAVANCE (MEROPENEM/RPX7009) VERSUS BEST AVAILABLE THERAPY IN SUBJECTS WITH SELECTED SERIOUS INFECTIONS DUE TO CARBAPENEM RESISTANT ENTERO... | |||||||||||||||||||||||||||||||||
Medical condition: serious infections, specifically complicated urinary tract infection (cUTI) or acute pyelonephritis (AP), complicated intra-abdominal infections (cIAI), hospital acquired bacterial pneumonia (HABP... | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: GB (Completed) IT (Completed) ES (Completed) GR (Completed) | |||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004544-38 | Sponsor Protocol Number: C3601009 | Start Date*: 2020-07-03 | |||||||||||
Sponsor Name:Pfizer Inc. | |||||||||||||
Full Title: A PROSPECTIVE, RANDOMIZED, OPEN-LABEL, COMPARATIVE STUDY TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF AZTREONAM-AVIBACTAM (ATM-AVI) AND BEST AVAILABLE THERAPY FOR THE TREATMENT OF SERIOUS INF... | |||||||||||||
Medical condition: SERIOUS INFECTIONS DUE TO MULTI-DRUG RESISTANT GRAM- NEGATIVE BACTERIA PRODUCING METALLO-Β-LACTAMASE (MBL) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Prematurely Ended) RO (Ongoing) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
